Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU. V114 contains the 13 serotypes included in Prevnar 13 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A), as well as two additional serotypes (22F and 33F). Merck & Co is testing both an aluminum-adjuvanted and non-adjuvanted version of the vaccine.
V114’s (15-valent pneumococcal conjugate vaccine; Merck & Co) broader serotype coverage gives it significant market potential,
should it demonstrate broader immunogenicity to Prevnar 13 (13-valent pneumococcal conjugate vaccine; Pfizer) in Phase III studies.
If serotype shift occurs, V114 could replace Prevnar 13 on the market for adults aged 50 years and older due to its broader coverage
and greater diversity in serotypes.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.